Spots Global Cancer Trial Database for Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
Official Title: A Multi Center, Open-label, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IM156 in Patients With Advanced Solid Tumors and Lymphoma
Study ID: NCT03272256
Conditions
Interventions
Study Description
Brief Summary: The main purpose of first-in-human IM156 study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose and recommended phase 2 dose of IM156.
Detailed Description:
Keywords
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
Asan Medical Center, Seoul, , Korea, Republic of
Yonsei University Severance Hospital, Seoul, , Korea, Republic of
Contact Details
Name: Sun Young Rha, MD, PhD
Affiliation: Department of oncology
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
